Patents by Inventor Jeffrey Leiden

Jeffrey Leiden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
    Publication number: 20060251626
    Abstract: This invention relates to the use of recombinant adeno-associated virus (rAAV) vectors to transduce cardiomyocytes in vivo by infusing the rAAV into a coronary artery or coronary sinus. rAAV infection is not associated with detectable myocardial inflammation or myocyte necrosis. Thus, rAAV is a useful vector for the stable expression of therapeutic genes in the myocardium and can be used to deliver genes for inducing angiogenesis, inhibiting angiogenesis, stimulating cell proliferation, inhibiting cell proliferation and/or treating or ameliorating other cardiovascular conditions.
    Type: Application
    Filed: June 9, 2006
    Publication date: November 9, 2006
    Applicant: Arch Development Corporation
    Inventors: Jeffrey Leiden, Eric Svensson
  • Genetically-engineered myoblasts and cardiac myocytes as drug delivery systems
    Publication number: 20020077311
    Abstract: A novel method for expressing a protein which comprises: transforming skeletal myoblasts or cardiac myocytes with a DNA sequence comprising a DNA segment encoding a selected gene downstream of the Rous sarcoma virus long terminal repeat or the expression sequence in pRSV, and implanting said skeletal myoblasts or cardiac myocytes into a recipient which then expresses a physiologically effective level of said protein.
    Type: Application
    Filed: September 13, 2001
    Publication date: June 20, 2002
    Applicant: The Regents of The University of Michigan
    Inventors: Jeffrey Leiden, Eliav Barr